NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BCTX

BriaCell Therapeutics Corp

Jul 03 • 04:00PM ET

2.91

Dollar change -0.02
Percentage change -0.68	%

Healthcare • Biotechnology • Canada • NASD

Peers: GILD PBYI JNJ EXEL BMY MRK BLUE AZN FOLD AMGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.25	Insider Own	6.47%	Shs Outstand	6.56M	Perf Week	-6.43%
Market Cap	19.73M	Forward P/E	-	EPS next Y	-1.77	Insider Trans	0.00%	Shs Float	6.34M	Perf Month	-14.66%
Enterprise Value	6.80M	PEG	-	EPS next Q	-1.39	Inst Own	3.67%	Short Float	3.32%	Perf Quarter	-19.39%
Income	-19.43M	P/S	-	EPS this Y	41.56%	Inst Trans	0.52%	Short Ratio	0.14	Perf Half Y	-66.03%
Sales	0.00M	P/B	1.54	EPS next Y	32.70%	ROA	-167.50%	Short Interest	0.21M	Perf YTD	-65.66%
Book/sh	1.89	P/C	1.58	EPS next 5Y	31.60%	ROE	-602.61%	52W High	29.40 -90.10%	Perf Year	-82.20%
Cash/sh	1.84	P/FCF	-	EPS past 3/5Y	54.33% 47.85%	ROIC	-156.54%	52W Low	2.78 4.68%	Perf 3Y	-96.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.03% 5.79%	Perf 5Y	-97.90%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-46.56%	Oper. Margin	-	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.41	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	40.15	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.41	EPS Q/Q	-201.85%	SMA20	-7.35%	Beta	1.12	Target Price	32.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-16.17%	Rel Volume	0.05	Prev Close	2.93
Employees	18	LT Debt/Eq	0.00	Earnings	Jun 16 AMC	SMA200	-58.51%	Avg Volume	1.53M	Price	2.91
IPO	Oct 28, 2010	Option/Short	No / Yes	EPS/Sales Surpr.	6.82% -	Trades		Volume	69,779	Change	-0.68%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-22	Initiated	H.C. Wainwright	Buy	$25

Jul-02-25 07:30AM	BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven (GlobeNewswire)
Jun-24-25 07:30AM	BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Jun-04-25 07:30AM	BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 (GlobeNewswire)
Jun-02-25 07:30AM	BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025 (GlobeNewswire)
May-27-25 07:30AM	BriaCell Bria-OTS Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor (GlobeNewswire)
07:30AM	Loading…
May-23-25 07:30AM	BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 (GlobeNewswire) -9.97%
May-20-25 07:30AM	BriaCell CEO Letter to Shareholders (GlobeNewswire) +11.25%
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire) -8.07%
Apr-30-25 07:30AM	BriaCell Reports Late-Breaker Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified (GlobeNewswire)
Apr-28-25 04:05PM	BriaCell Therapeutics Announces Closing of $13.8 million Public Offering (GlobeNewswire) -8.20%
07:30AM	BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+ Development (GlobeNewswire)
Apr-24-25 08:00PM	BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering (GlobeNewswire) +11.05% -13.76%
07:30AM	BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS (GlobeNewswire)
Apr-23-25 07:30AM	BriaCell Announces Four Clinical Data Presentations at ASCO 2025 (GlobeNewswire)
Apr-22-25 07:30AM	BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) (GlobeNewswire) +27.68%
07:30AM	Loading…
Apr-16-25 07:30AM	BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer (GlobeNewswire) +19.47%
Apr-10-25 08:00AM	BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3 (GlobeNewswire)
Mar-26-25 08:00AM	BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference (GlobeNewswire)
Mar-20-25 08:00AM	Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Feb-05-25 06:15PM	BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting (GlobeNewswire) +9.27% -9.60%
04:05PM	BriaCell Therapeutics Announces Closing of Public Offering (GlobeNewswire)
Feb-03-25 07:59PM	BriaCell Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -18.65%
04:45PM	BriaCell Therapeutics Announces Proposed Public Offering of Common Shares (GlobeNewswire)
07:30AM	BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS (GlobeNewswire)
Jan-27-25 06:42PM	BriaCell Announces Completion of 15:1 Share Consolidation (GlobeNewswire)
Jan-03-25 05:05PM	BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 (GlobeNewswire) +10.47% -28.55%
05:05PM	BriaCell Announces Proposed Effective Date of Share Consolidation (GlobeNewswire)
Dec-17-24 04:05PM	BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures (GlobeNewswire) +6.17%
04:05PM	BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures (GlobeNewswire)
Dec-13-24 04:05PM	BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering (GlobeNewswire) -7.86%
07:50AM	Loading…
07:50AM	BriaCell 2024 SABCS Poster Highlights Ability of Bria-IMT Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer (GlobeNewswire)
Dec-11-24 11:54PM	BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering (GlobeNewswire) -39.89%
04:05PM	BriaCell Therapeutics Announces Proposed Public Offering (GlobeNewswire)
07:50AM	BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS (GlobeNewswire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire) +12.99%
07:50AM	BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Nov-26-24 07:50AM	BriaCell 2024 SABCS Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer (GlobeNewswire) +9.71%
Nov-25-24 07:50AM	BriaCell Provides Update to its Board of Directors (GlobeNewswire) -6.67%
Nov-21-24 07:50AM	BriaCell Announces First Patient Dosed with Bria-OTS in Metastatic Breast Cancer Study (GlobeNewswire) +31.00%
Nov-08-24 07:50AM	BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference (GlobeNewswire)
Nov-04-24 07:50AM	BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium , December 10 13 (GlobeNewswire)
Oct-22-24 07:50AM	BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data (GlobeNewswire) +9.55%
Oct-15-24 07:50AM	BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study (GlobeNewswire)
Oct-02-24 04:05PM	BriaCell Therapeutics Announces Closing of $5 Million Offering (GlobeNewswire) +24.69%
Oct-01-24 02:05PM	BriaCell Therapeutics Announces $5 Million Offering (GlobeNewswire) -34.68%
07:50AM	BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor (GlobeNewswire)
Sep-18-24 07:50AM	BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients (GlobeNewswire) +11.34%
Sep-12-24 04:05PM	BriaCell Therapeutics Announces Closing of $8.5 Million Offering (GlobeNewswire) -11.03%
Sep-11-24 12:09PM	BriaCell Therapeutics Announces $8.5 Million Offering (GlobeNewswire)
07:50AM	BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer (GlobeNewswire)
Sep-10-24 07:50AM	BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer (GlobeNewswire) -8.90%
Sep-09-24 07:50AM	BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -6.72%
Jul-18-24 07:56AM	BriaCell Quadruples Progression Free Survival (PFS) in Patient with Eye-Bulging Metastatic Breast Cancer (GlobeNewswire) -17.49%
Jun-14-24 09:52PM	BCTX Stock Earnings: BriaCell Therapeutics Beats EPS for Q3 2024 (InvestorPlace)
Jun-03-24 08:00AM	BriaCell Presents Clinical Efficacy Data at ASCO 2024 (GlobeNewswire) -9.47%
May-30-24 08:00AM	BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer (GlobeNewswire)
May-28-24 08:00AM	BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study (GlobeNewswire)
07:27AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-24-24 08:00AM	BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024 (GlobeNewswire)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-17-24 04:33PM	BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering (GlobeNewswire) +7.19%
May-15-24 08:00AM	BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering (GlobeNewswire) -22.75%
Apr-24-24 08:00AM	BriaCell Announces Oral and Poster Presentations at ASCO 2024 (GlobeNewswire) -5.60%
Apr-10-24 08:00AM	BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer (GlobeNewswire)
Apr-09-24 08:00AM	BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR (GlobeNewswire)
Mar-19-24 06:52AM	BCTX Stock Earnings: BriaCell Therapeutics Reported Results for Q2 2024 (InvestorPlace) -6.55%
Mar-07-24 08:00AM	BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies (GlobeNewswire) -7.05%
Mar-06-24 08:00AM	BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference (GlobeNewswire) -8.24%
Feb-27-24 08:00AM	BriaCell Provides Update on Alleged Illegal Trading of Public Securities (GlobeNewswire)
Feb-07-24 08:00AM	BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case (GlobeNewswire)
Feb-06-24 08:30AM	Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing (GlobeNewswire) +5.34%
Jan-30-24 10:48PM	BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting (GlobeNewswire)
Jan-04-24 08:45AM	BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with Eye-Bulging Metastatic Breast Cancer (GlobeNewswire) +6.60%
Dec-28-23 08:55AM	BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients (GlobeNewswire)
Dec-20-23 08:40AM	BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset (GlobeNewswire)
Dec-06-23 09:31AM	BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS (GlobeNewswire)
09:00AM	BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit (GlobeNewswire)
Nov-30-23 07:00AM	BriaCell Records New Responder with Remarkable Improvement of Eye-Bulging Metastatic Tumor (GlobeNewswire)
Nov-03-23 08:31AM	BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS IND (GlobeNewswire) +9.41%
Nov-01-23 10:49AM	BCTX: Year in Review (Zacks) -7.53%
Oct-25-23 09:15AM	BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate (GlobeNewswire)
Oct-20-23 09:15AM	October is Breast Cancer Awareness Month BriaCell is Leading the Fight with its Innovative Technology (GlobeNewswire) -5.51%
Oct-18-23 09:00AM	BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences (GlobeNewswire) -5.26%
Oct-11-23 09:10AM	BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic (GlobeNewswire)
Oct-04-23 09:00AM	BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer (GlobeNewswire)
Oct-03-23 09:00AM	BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer (GlobeNewswire)
Sep-08-23 07:00AM	BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer (GlobeNewswire)
Aug-31-23 11:54AM	BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders (GlobeNewswire)
08:21AM	BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer (GlobeNewswire)
Aug-25-23 02:33PM	BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders (GlobeNewswire)
Aug-18-23 12:21PM	BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting (GlobeNewswire)
Aug-16-23 08:36AM	BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS Immunotherapy for Cancer (GlobeNewswire)
Jul-10-23 07:00AM	BCTX: Pivotal Study Protocol Cleared (Zacks)
Jun-27-23 08:05AM	FDA Approves BriaCells Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer (GlobeNewswire) -7.99%
May-25-23 09:00AM	BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp. (GlobeNewswire)
May-19-23 11:38AM	BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share (GlobeNewswire) +5.59%
May-15-23 08:00AM	BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc. (GlobeNewswire)
Apr-27-23 05:33AM	BCTX: Posters Galore at AACR (Zacks Small Cap Research)
Apr-17-23 07:45AM	BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR (GlobeNewswire) +5.28%
Apr-10-23 07:29AM	BriaCell Therapeutics (TSE:BCT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCTX

BriaCell Therapeutics Corp

Upgrade your FINVIZ experience